NFKB1 and Huntington disease: Here we show that laquinimod, a brain-penetrant immunomodulatory agent previously shown to mitigate excessive NF-kB activation in the periphery and CNS31, improves neuropathology and some behavioural deficits in the YAC128 HD mice.